Status:

COMPLETED

Labetalol to Prevent Hypertension and Tachycardia During Fiberoptic Bronchoscopy

Lead Sponsor:

Rabin Medical Center

Conditions:

Bronchoscopy

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Passing a bronchoscope through the airways frequently causes a stress response even though patients are sedated. This stress response is usually an increase in pulse and blood pressure, which may have...

Eligibility Criteria

Inclusion

  • All patients over 18 years old undergo fiberoptic bronchoscopy in our unit

Exclusion

  • inability or refusal to give informed consent
  • bronchoscopy through an artificial airway
  • intolerance or allergy to the study drug
  • bradycardia (HR\<60/min) or hypotension (systolic BP \<100) at screening
  • pregnancy,
  • concomitant treatment with diltiazem or verapamil
  • intention to use propofol as the sedative agent for bronchoscopy.

Key Trial Info

Start Date :

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2007

Estimated Enrollment :

72 Patients enrolled

Trial Details

Trial ID

NCT00394537

End Date

May 1 2007

Last Update

June 6 2007

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Rabin Medical Center

Petah Tikva, Israel, 49100

Labetalol to Prevent Hypertension and Tachycardia During Fiberoptic Bronchoscopy | DecenTrialz